Status:
UNKNOWN
COVID-19 Hyper Coagulability Care by LLLT
Lead Sponsor:
Cairo University
Conditions:
COVID-19 Pneumonia
Eligibility:
All Genders
35-45 years
Phase:
NA
Brief Summary
COVID-19 clotting Safety
Detailed Description
Covid-19 patients have liability for hyper coagulability, low level laser Therapy improve circulation and decrease liability for hyper coagulability accompanied with circulatory exercises .
Eligibility Criteria
Inclusion
- BMI from 18.5 to 29.9 kg/m2
- Moderate elevated percentage of coagulative factors for COVID-19 Diagnosis:
- Nasopharyngeal swab
- Sepsis induced coagulopathy score\>4
- D\_dimer≥0,5mg/L
- Fibrinogen\>2,5gm/L
- C\_reactive protein≥10mg/L
- Lymphocyte count\<1,500mm3
- Platelet count\<150,000mm3
- Prothrombin time increase\>3sec
- Activated partial thromboplastin time increase\>5sec
- Same level of physical activity
- Patients can swallow tablets
- CT scan screening method for COVID-19 Diagnosis
- Physical examination
Exclusion
- hyper tension
- Cognitive impairment e.g (delirium)
- Diabetes mellitus both types dependant or non
- Disabled musculoskeletal Disorders e.g hemi paresis
- Coronary artery diseases and heart failure
- DVT
- Stroke, bone disease, renal failure, pulmonary embolism
- Vitamins deficiency
- 6 months post large surgeries
- Alcohol intake and smokers
- Thyroid diseases
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 4 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05271461
Start Date
February 1 2022
End Date
June 4 2022
Last Update
March 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Physical therapy faculty
Dokki, Giza Governorate, Egypt, 12611